Research programme: nitric oxide therapeutics topical - Novan Therapeutics

Drug Profile

Research programme: nitric oxide therapeutics topical - Novan Therapeutics

Alternative Names: CR 2005; CR 2016; Nitric Oxide Advanced Healing technology - Novan Therapeutics; NOAH technology - Novan Therapeutics; NVN 4428; NVN-4000; SB 414

Latest Information Update: 22 Nov 2016

Price : $50

At a glance

  • Originator Novan Inc
  • Class Antiacnes; Antiandrogens; Antibacterials; Antihypertensives; Antivirals; Free radicals; Nitrogen oxides; Non-opioid analgesics; Small molecules; Vasodilators
  • Mechanism of Action Angiogenesis inducing agents; Nitric oxide stimulants; Reactive oxygen species modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Atopic dermatitis; Psoriasis
  • Discontinued Burns; Onychomycosis; Staphylococcal infections; Wound infections; Wounds

Most Recent Events

  • 20 Mar 2017 Novan announces intention to submit an IND application for SB 414 for Psoriasis
  • 22 Nov 2016 Discontinued - Preclinical for Wounds in USA (Topical)
  • 22 Nov 2016 Preclinical trials in Psoriasis in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top